tm logo
X PARSOLEX PARTNER SOLUTIONS EXCELLENCE
Live/Registered
REGISTERED

on 18 May 2021

Last Applicant/ Owned by

3070 Kent Avenue

West Lafayette

IN

47906

Serial Number

88570483 filed on 07th Aug 2019

Registration Number

6356727 registered on 18th May 2021

in the Principal Register

Correspondent Address

Jill J. Chalmers

BRYAN CAVE LEIGHTON PAISNER LLP

90 SOUTH CASCADE AVENUE, SUITE 1300

COLORADO SPRINGS, CO 80903

Filing Basis

1. intent to use

2. use application currently

Disclaimer

"SOLUTIONS"

X PARSOLEX PARTNER SOLUTIONS EXCELLENCE

Consulting services in the fields of pharmaceutical, medical and healthcare research and development; technical services, namely, research and development in the pharmaceutical and biotechnology fields; consulting services for pharmaceutical formulation design, design of processes to transform inorganic and organic substances and pharmaceutical technology transfer being advice and information abouRead More

Classification Information


Class [042]
Computer & Software Services & Scientific Services


Consulting services in the fields of pharmaceutical, medical and healthcare research and development; technical services, namely, research and development in the pharmaceutical and biotechnology fields; consulting services for pharmaceutical formulation design, design of processes to transform inorganic and organic substances and pharmaceutical technology transfer being advice and information about pharmaceutical research and design; technical services, namely, providing advice, information and instructions for pharmaceutical formulation design and design of processes to transform inorganic and organic substances, pharmaceutical technology transfer being advice and information about pharmaceutical research and design; pharmaceutical product chemical and physical evaluation services, namely, test method development, test method validation, use of test methods for in-process control, quality control, and product release, and technology transfer being advice and information about pharmaceutical test methods; analytical chemistry services, namely, developing and validating test methods for drug product release; technology transfer being advice and information about the drug product testing process and test methods; providing services to others in the fields of analytical, chemistry and manufacturing controls for the production and regulatory approval of pharmaceuticals, namely, providing scientific information relating to the analysis and management of the pharmaceutical manufacturing process for the production, packaging, and regulatory approval of pharmaceuticals; consulting services in the fields of chemistry, biotechnology, pharmaceutical research and development, laboratory testing, and diagnostics; consulting and research and development services in the fields of analytical chemistry, biochemistry, medicinal chemistry, drug development, biotechnology, microbiology and molecular biology; technical consulting in the fields of pharmaceutical studies, research and development; technical consulting in the field of pharmaceutical development and engineering; technical consulting in the field of analytical chemistry services; consultancy pertaining to pharmacology; technology consultation in the fields of research and development of pharmaceuticals, medicines and healthcare products; scientific research consulting in the fields of pharmaceuticals, medicines and healthcare products; product development consulting in the fields of pharmaceuticals, medicines and healthcare products; scientific research services relating to pharmaceuticals, medicines and healthcare products; product development consultation; product development services; formulation and process design services for drug products for others; outsource service provider for manufacturing and packaging of pharmaceuticals; formulation and process design services for drug products for others; design of packaging for pharmaceuticals of others; pharmaceutical product packaging design services for others; formulation and process design services for drug products of others; provision of information, advice and consultancy in relation to pharmaceutical packaging design; technical consulting in the field of pharmaceutical research and development; custom pharmaceutical service provider, namely, pharmaceutical formulation design, design of processes to transform inorganic and organic substances, and chemical and physical evaluation of pharmaceuticals; consulting in the areas of pharmaceutical formulation design, design of processes to transform inorganic and organic substances, and chemical and physical evaluation of pharmaceuticals; development of custom pharmaceuticals for others; design of packaging for pharmaceuticals for others; formulation and process design services for drug products for others


First Use Date in General

28th Oct 2019

First Use Date in Commerce

28th Oct 2019

Mark Details


Serial Number

No 88570483

Mark Type

No Service Mark

Attorney Docket Number

No 1087939.4

44D Filed

No

44D Current

No

44E filed

No

44E Current

No

66A Filed

No

66A Current

No

Current Basis

No

No Basis

No

Design Code(s)

02.11.01 -

Hearts

10.09.01 -

Medicines and nonmedical products in tablet, capsule or powder form; suppositories

24.15.04 -

Arrowheads

24.15.10 -

More than one arrow

Description of Design Search

The mark consists of a stylized design comprised of two diagonal intersecting pill capsules forming a heart shaped arrow design on the left side and creating an "x" shape; the design element appears to the left of the wording "Parsolex"; centered underneath the design and "Parsolex" wording appears the wording "PARTNER SOLUTIONS EXCELLENCE".

Legal History


Show more

Status DateAction Taken
18th May 2021REGISTERED-PRINCIPAL REGISTER
16th Apr 2021NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
15th Apr 2021ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
02th Apr 2021STATEMENT OF USE PROCESSING COMPLETE
01st Apr 2021CASE ASSIGNED TO INTENT TO USE PARALEGAL
17th Mar 2021TEAS STATEMENT OF USE RECEIVED
17th Mar 2021USE AMENDMENT FILED
22nd Sep 2020NOA E-MAILED - SOU REQUIRED FROM APPLICANT
28th Jul 2020PUBLISHED FOR OPPOSITION
28th Jul 2020OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED